Skip to Content

Keynote A39: Enfortumab Vedotin + Pembrolizumab agroundbreaking First Line Treatment in Untreated la/mUC

For over four decades, chemotherapy has been the cornerstone of treatment in locally advanced or
metastatic urothelial carcinoma. Today, we are at the cusp of a transformative shift. A groundbreaking combination therapy has emerged, achieving a notable 55% reduction in progression rates and an over 50% decrease in the risk of mortality. Dr. Thomas Powles states that if given the opportunity, he would change his treatment for these patients tomorrow.

Thomas Powles

Get access

If you are a doctor, nurse, or other health professionals, you can access the entire article by creating a profile on BestPractice Nordic.

Back to top